This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Asia Bio Partnering Forum
Save the date!
September 9–10, 2025Singapore

Anand Gautam
Founder at G2OME CONSULTING PTY LTD
Speaker

Profile

Anand is Founder of G2OME CONSULTING, Australia (since Feb 2024), where his aim is to help Translate Discoveries towards new Medicine. Anand is the former Executive Director and Head of External Science & Innovation (ES&I) at Pfizer, responsible for building academic and industry partnerships in Australia, New Zealand, and Southeast Asia, to fill the company’s pipeline with novel therapeutics. Prior to Pfizer, Anand worked as a Director/Senior Director for R&D Innovation Sourcing at Novo Nordisk, Denmark, setting directions to innovation sourcing strategy at the company; formed OmGenix BioSolutions, a consultancy company; and worked as a vice-president of research and development at Progen in Brisbane, where he managed and initiated Phase I to III clinical trials. He has also worked as a senior vice-president at Pharmexa, Denmark, where he headed research and external collaborations.

Anand has a strong background in scientific and commercial management of research at various academic institutions and biotechnology companies around the world. In addition, he brings direct experience in drug discovery, drug development with late-stage clinical trials, and commercialisation of translatable science from academia.

Anand completed his PhD from University of London in Immunology, undertook postdoctoral training in immunology at Stanford University in California, US. He was then appointed as a research fellow, and later a leader, at John Curtin School of Medical Research, The Australian National University. He was also appointed as an associate professor at UQ’s former Diamantina Centre for Immunology and Cancer Research.

Agenda Sessions

  • Innovation and Collaboration in Asia: Current status and future directions

    4:00pm
  • AI-aided drug discovery: taking action, gaining momentum, and latest developments

    4:00pm

At this event